Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2011 3
2012 3
2013 3
2014 10
2015 13
2016 9
2017 4
2018 5
2019 5
2020 7
2021 5
2022 7
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: mondello p. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Nowakowski GS, et al. Among authors: mondello p. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648. Clin Cancer Res. 2022. PMID: 35674661 Free PMC article.
Insights into the tumor microenvironment of B cell lymphoma.
Ng WL, Ansell SM, Mondello P. Ng WL, et al. Among authors: mondello p. J Exp Clin Cancer Res. 2022 Dec 29;41(1):362. doi: 10.1186/s13046-022-02579-9. J Exp Clin Cancer Res. 2022. PMID: 36578079 Free PMC article. Review.
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.
Mondello P, Paludo J, Novak JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Dasari S, Manske MK, Abeykoon JA, Sarangi V, Kapoor P, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan AA, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Mondello P, et al. Clin Cancer Res. 2023 Mar 1;29(5):957-970. doi: 10.1158/1078-0432.CCR-22-2215. Clin Cancer Res. 2023. PMID: 36534518
Emerging drugs for diffuse large B-cell lymphoma.
Mondello P, Younes A. Mondello P, et al. Expert Rev Anticancer Ther. 2015 Apr;15(4):439-51. doi: 10.1586/14737140.2015.1009042. Epub 2015 Feb 5. Expert Rev Anticancer Ther. 2015. PMID: 25652253 Review.
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H. Merryman RW, et al. Among authors: mondello p. Hemasphere. 2023 Jan 24;7(2):e826. doi: 10.1097/HS9.0000000000000826. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36713355 Free PMC article.
75 results